1.28
-0.01(-0.78%)
Currency In USD
| Previous Close | 1.29 |
| Open | 1.29 |
| Day High | 1.3 |
| Day Low | 1.26 |
| 52-Week High | 1.84 |
| 52-Week Low | 0.81 |
| Volume | 208,800 |
| Average Volume | 1.2M |
| Market Cap | 68.11M |
| PE | -0.81 |
| EPS | -1.59 |
| Moving Average 50 Days | 1.39 |
| Moving Average 200 Days | 1.25 |
| Change | -0.01 |
If you invested $1000 in PMV Pharmaceuticals, Inc. (PMVP) since IPO date, it would be worth $34.12 as of December 04, 2025 at a share price of $1.28. Whereas If you bought $1000 worth of PMV Pharmaceuticals, Inc. (PMVP) shares 3 years ago, it would be worth $129.42 as of December 04, 2025 at a share price of $1.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire Inc.
Oct 24, 2025 3:39 PM GMT
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, co
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:01 PM GMT
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 1
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR)